RecruitingNCT04981795

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

realMIND: A Multicenter, Observational Study to Characterize the Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in US Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma With a Focus on Racial and Ethnic Minority Patients

Sponsor

Incyte Corporation

Enrollment

100 participants

Start Date

Sep 20, 2021

Study Type

OBSERVATIONAL

Summary

The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a real-world observational study tracking patients with relapsed or treatment-resistant diffuse large B-cell lymphoma (DLBCL) — a type of aggressive blood cancer — who are receiving the drug combination tafasitamab plus lenalidomide. The study collects data on how well it works and any side effects in everyday clinical practice. **You may be eligible if...** - You are 18 or older with relapsed or refractory DLBCL (cancer came back or didn't respond to prior treatment) - You are starting or have started tafasitamab treatment - You have had at least one prior treatment for DLBCL - Your DLBCL diagnosis has been confirmed by a pathologist **You may NOT be eligible if...** - Your DLBCL subtype is not included in the study criteria - You do not meet the standard medical requirements for this treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTafasitamab

Observational Study on safety and effectiveness of tafasitamab in combination with lenalidomide inPatients With Relapsed or Refractory DLBCL.

Locations(25)

Alabama Oncology

Birmingham, Alabama, United States

Clearview Cancer Institute

Huntsville, Alabama, United States

University of California, Irvine Medical Center

Orange, California, United States

McFarland Clinic P.C.

Ames, Iowa, United States

Mission Cancer and Blood

Des Moines, Iowa, United States

Tulane Cancer Center

New Orleans, Louisiana, United States

American Oncology Partners of Maryland PA

Bethesda, Maryland, United States

University of Michigan Comprehensive Cancer Center Michigan Medicine

Ann Arbor, Michigan, United States

Henry Ford Health System

Detroit, Michigan, United States

Morristown Medical Center

Morristown, New Jersey, United States

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

Westchester Medical Center

Hawthorne, New York, United States

Levine Cancer Institute

Charlotte, North Carolina, United States

VA Medical Center - Durham

Durham, North Carolina, United States

Leo Jenkins Cancer Center/ECU School of Medicine

Greenville, North Carolina, United States

Mercy Medical Center

Canton, Ohio, United States

Ohio Health Marion Area Physicians

Marion, Ohio, United States

Tri County Hematology & Oncology Associates, Inc

Massillon, Ohio, United States

Integris Cancer Institute of Oklahoma

Oklahoma City, Oklahoma, United States

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Lankenau Medical Center

Wynnewood, Pennsylvania, United States

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

UW Medicine

Seattle, Washington, United States

Yakima Valley Memorial Hospital/North Star Lodge

Yakima, Washington, United States

Froedtert & Medical College Clinics

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04981795